Form 8-K - Current report:
SEC Accession No. 0001193125-25-143187
Filing Date
2025-06-20
Accepted
2025-06-20 07:00:37
Documents
13
Period of Report
2025-06-17
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d50241d8k.htm   iXBRL 8-K 27368
2 EX-4.1 d50241dex41.htm EX-4.1 85559
  Complete submission text file 0001193125-25-143187.txt   257724

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA antx-20250617.xsd EX-101.SCH 2874
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE antx-20250617_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE antx-20250617_pre.xml EX-101.PRE 11723
15 EXTRACTED XBRL INSTANCE DOCUMENT d50241d8k_htm.xml XML 3759
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 251059052
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)